Predictive value of preoperative serum sialyl Lewis X-i antigen levels in non-small cell lung cancer

Anticancer Research

Volumn 18, Issue 4 B, 1998, Pages 2865-2868

  Satoh, Hiroaki ^a   Ishikawa, Hiroichi ^a   Yamashita, Yuko T ^a   Takahashi, Hideto ^a   Ishikawa, Shigemi ^a   Kamma, Hiroshi ^a   Ohtsuka, Morio ^a   Hasegawa, Shizuo ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Mediastinal lymph node involvement; Non small cell lung cancer; Sialyl Lewis X i antigen

Indexed keywords

SIALYL LEWIS X I ANTIGEN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD GROUP LEWIS SYSTEM; BLOOD LEVEL; CONTROLLED STUDY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM LYMPH NODE; PRIORITY JOURNAL; RADIOIMMUNOASSAY;

AGED; ANTIGENS, CD15; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LEWIS BLOOD-GROUP SYSTEM; LUNG NEOPLASMS; MALE; MIDDLE AGED; OLIGOSACCHARIDES; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 0031813506     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Travis WD, Lubin J, Ries L, et al. United States lung carcinoma incidence trends: declining for most histologoc types among males, increasing among females. Cancer 77: 2464-2470, 1996.
2. Statistics and Information Department, Minister's Secretariat, Ministry of Health and Welfare. Vital Statistics, Japan. 1995.
3. Goldstraw P, Mannam GC, Kaplan DK, et al: Surgical management of non-small-cell lung cancer with ipsilateral mediastinal node metastasis (N2 disease). J Thorac Cardiovasc Surg 107: 19-28, 1994.
4. Mountain CF, Lukeman JM, Hammar SP, et al: Lung cancer classification: the relationship of disease extent and cell type to survival in a clinical trials population. J Surg Oncol 35: 147-156, 1987.
5. Pearson FG, DeLarue NC, Ilues R, et al: Significance of positive superior mediastinal nodes identified at mediastinoscopy in patients with resectable cancer of the lung. J Thorac Cadiovasc Surg 83: 1-11, 1982.
6. Martini N, Flehinger BJ: The role of surgery in N2 lung cancer. Sur Clin North Am 67: 1037-1049, 1987.
7. Naruke T, Goya T, Tsuchiya R, et al: The importance of surgery to non-small cell carcinoma of the lung. Ann Thrac Surg 46: 603-610, 1988.
8. Failing LJ, Pugatch RD, Jung-Legg Y: Computed tomography scanning the mediastinum in the staging of bronchogenic carcinoma. Am Rev Respir Dis 124: 690-695, 1981.
9. Baron RL, Levitt RG, Sagelss SS, et al: Computed tomography in preoperative evaluation of bronchogenic carcinoma. Radiology 145: 727-732, 1982.
10. McKenna RJ Jr, Libshitz HZ, Mountain CE, et al: Roentgenographic evaluation of mediastinal nodes for preoperative assessment in lung cancer. Chest 88: 206-210, 1985.
11. Staples CA, Muller NL, Miller RR, et al: Mediastinal nodes in bronchogenic carcinoma; comparison between CT and mediastinoscopy. Radiology 167: 362-372, 1988.
12. Webb WR, Gatsonis C, Zerhouni E, et al: CT and MRI in staging non-small cell bronchogenic carcinoma, report of the Radiographic Diagnostic Oncology Group. Radiology 178: 705-713, 1991.
13. Chiti A, Maffioli LS, Infante M, et al: Assessment of mediastinal involvement in lung cancer with technetium-99m-sestamibi SPECT. J Nucl Med 37: 938-942, 1996.
14. 18F]FDG positron emmission tomography (PET). Thorax 52: 438-441, 1997.
15. Kwekkeboom DJ, Kho GS, Lamberts SW, et al: The value of octreotide scintigraphy in patients with lung cancer. Eur J Nuc Med 21: 1106-1113, 1994.
16. Mountain CF: Revisions in the International System for Staging Lung Cancer. Chest 111: 1710-1717, 1997.
17. World Health Organization. Histological Typing of the Lung Tumors. Am J Clin Pathol 77: 123-36, 1982.
18. Hanley JA, McNeil BJ: The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143: 29-36, 1982.
19. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations J Am Stat Assoc 53: 457-481, 1958.
20. Cox DR: Regression models and life tables. J R Statist Soc B 34: 187-220, 1972.
21. Moro D, Villemain D, Vuillez JP, et al: CEA, CYFRA21-1 and SCC in non-small cell lung cancer. Lung Cancer 1 3: 169-176, 1995.
22. Diez M, Gomez A, Hernando F, et al: Serum CEA, CA125, and SCC antigens and tumor recurrence in resectable non-small cell lung cancer. Int J Biol Markers 10: 5-10, 1995.
23. Picardo AL, Torres AJ, Maestro M, et al: Quantitative analysis of carcinoembryonic antigen, squamous cell carcinoma antigen, CA125, and CA50 cytosolic content in non-small cell lung cancer. Cancer 73: 2305-2311, 1994.
24. Margolis ML, Hyzy JB, Schenken LL, et al: Serum tumor markers in non-small cell lung cancer. A comparative analysis. Cancer 73: 605-609, 1994.
25. Kannagi R, Fukushi Y, Tachikawa T, et al: Quantitative and qualitative characterization of human cancer-associated serum glycoprotein antigens expressing fucosyl or sialyl-fucosyl type 2 chain polylactosamine. Cancer Res 46: 2619-2626, 1986.
26. Zenita R, Kirihara Y, Kitahara A, et al: Fucosylated type-2 chain polylactosamine antigen in human lung cancer. Int J Cancer 41: 344-349, 1988.
27. Satoh H, Yano H, Naitoh T, et al: Determination of various tumor markers, with special reference to sialyl SSEA-I antigen in lung cancer. Jpn J Cancer Chemother 15: 2917-2922, 1988.
28. Satoh H, Ishikawa H, Kamma H, et al: Serum sialyl Lewis X-i antigen levels in non-small cell lung cancer: correlation with distant metastasis and survival. Clin Cancer Res 3: 495-499, 1997.
29. Buccheri G, Ferrigno D: The tissue polypeptide antigen serum test in the preoperative evaluation of non-small cell lung cancer. Diagnostic yield and comparison with conventional staging methods. Chest 107: 471-476, 1995.
30. Maggi G, Casadio C, Giobbe R, et al: The value of selective mediastinoscopy resectability of patients with bronchogenic carcinoma. Int Surg 77: 280-283, 1992.
31. Kobayashi J, Kitamura S: Evaluation of lymph nodes on computed tomography images in epidermoid lung cancer. Intern Med 34: 507-513, 1995.